dr. reddy's labs glp-1 receptor agonist medications Laboratories has received approval from Health Canada for its generic semaglutide injection, strengthening the Indian drugmaker's presence in the fast-growing global market for diabetes therapies. The company said on A Comprehensive Review of the

This acquisition is aimed at enhancing its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.

Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Looking for the best laxative for GLP-1 constipation

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.